Literature DB >> 26396688

Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.

Naohisa Ogo1, Yoshinobu Ishikawa2, Jun-Ichi Sawada1, Kenji Matsuno1, Akihiro Hashimoto3, Akira Asai1.   

Abstract

Kinesin spindle protein (KSP), known as Hs Eg5, a member of the kinesin-5 family, plays an important role in the formation and maintenance of the bipolar spindle. We previously reported S-trityl-l-cysteine derivatives as selective KSP inhibitors. Here, we report further optimizations using docking modeling in the L5 allosteric binding site, which led to the discovery of several high affinity derivatives with two fused phenyl rings in the trityl group giving low nanomolar range KSP ATPase inhibition. The representative derivatives potently inhibited cell growth of HCT116 cells in correlation with KSP inhibitory activities and significantly suppressed tumor growth in the xenograft model in vivo.

Entities:  

Keywords:  HCT-116 xenograft model; Kinesin spindle protein; differential scanning fluorimetry; l-cysteine derivative; molecular modeling

Year:  2015        PMID: 26396688      PMCID: PMC4569872          DOI: 10.1021/acsmedchemlett.5b00221

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 3.  Targeting the kinesin spindle protein: basic principles and clinical implications.

Authors:  Vasiliki Sarli; Athanassios Giannis
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 4.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

Review 5.  Eribulin mesylate.

Authors:  Sarika Jain; Linda T Vahdat
Journal:  Clin Cancer Res       Date:  2011-08-22       Impact factor: 12.531

Review 6.  Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

Authors:  Hala Bakr El-Nassan
Journal:  Eur J Med Chem       Date:  2013-02-05       Impact factor: 6.514

7.  Structure-activity relationship and multidrug resistance study of new S-trityl-L-cysteine derivatives as inhibitors of Eg5.

Authors:  Hung Yi Kristal Kaan; Johanna Weiss; Dominik Menger; Venkatasubramanian Ulaganathan; Katarzyna Tkocz; Christian Laggner; Florence Popowycz; Benoît Joseph; Frank Kozielski
Journal:  J Med Chem       Date:  2011-02-23       Impact factor: 7.446

8.  S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.

Authors:  Dimitrios A Skoufias; Salvatore DeBonis; Yasmina Saoudi; Luc Lebeau; Isabelle Crevel; Robert Cross; Richard H Wade; David Hackney; Frank Kozielski
Journal:  J Biol Chem       Date:  2006-02-28       Impact factor: 5.157

Review 9.  Kinesins and cancer.

Authors:  Oliver Rath; Frank Kozielski
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

10.  Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.

Authors:  Fang Wang; James A D Good; Oliver Rath; Hung Yi Kristal Kaan; Oliver B Sutcliffe; Simon P Mackay; Frank Kozielski
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

View more
  1 in total

Review 1.  Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.

Authors:  Stephanie M Myers; Ian Collins
Journal:  Future Med Chem       Date:  2016-03-15       Impact factor: 3.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.